Ruth Oliver

Ruth Oliver

Company: UCB

Job title: Vice President and Head of Quantitative Pharmacology and DMPK


Bimekizumab in Moderate to Severe Plaque Psoriasis: A Model Informed Drug Development (MIDD) Journey from Discovery through Clinical Development Driving Key Decision Making and Optimized Posology 11:00 am

• Examining the application of quantitative approaches to drug design • Exploring early dose ranging and application of Bayesian approaches for decision making in a proof of concept • Demonstrating the optimal dose ranging and maintenance dose interval evaluation using model-based approaches • Design of phase 3: endpoint and time-point and H2H using population PK-PD…Read more

day: Day 2 AM - Track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.